| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2017.76.9901 |
| P698 | PubMed publication ID | 29355075 |
| P50 | author | Ray McDermott | Q40546925 |
| Sara Lonardi | Q50876272 | ||
| Scott Kopetz | Q51789838 | ||
| Thierry André | Q56250413 | ||
| Massimo Aglietta | Q60538695 | ||
| Bart Neyns | Q77226495 | ||
| P2093 | author name string | Andrew Hill | |
| Eric Van Cutsem | |||
| Heinz-Josef Lenz | |||
| Michael J Overman | |||
| Rebecca A Moss | |||
| Michael A Morse | |||
| Michael B Sawyer | |||
| Alain Hendlisz | |||
| Magali Svrcek | |||
| Shital Kamble | |||
| Fabio Gelsomino | |||
| Jean-Marie Ledeine | |||
| Ka Yeung Mark Wong | |||
| Z Alexander Cao | |||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colorectal cancer | Q188874 |
| microsatellite | Q265193 | ||
| DNA mismatch repair | Q2984243 | ||
| P304 | page(s) | 773-779 | |
| P577 | publication date | 2018-01-20 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer | |
| P478 | volume | 36 |
| Q90643334 | A Robust 6-lncRNA Prognostic Signature for Predicting the Prognosis of Patients With Colorectal Cancer Metastasis |
| Q103800717 | A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention |
| Q92582493 | A novel human monoclonal antibody specific to the A33 glycoprotein recognizes colorectal cancer and inhibits metastasis |
| Q96816430 | A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies |
| Q90702699 | A systematic review of salvage therapies in refractory metastatic colorectal cancer |
| Q64070843 | Antigen Targets for the Development of Immunotherapies in Leukemia |
| Q92376089 | Antitumor T-cell Homeostatic Activation Is Uncoupled from Homeostatic Inhibition by Checkpoint Blockade |
| Q92922662 | Application of Bayesian predictive probability for interim futility analysis in single-arm phase II trial |
| Q59798112 | Approach to evaluating tumor mutational burden in routine clinical practice |
| Q92278971 | Association of DNA repair gene polymorphisms with colorectal cancer risk and treatment outcomes |
| Q93211071 | Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status |
| Q90023691 | Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial |
| Q90292803 | Authors' Reply to Yu: "Outcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registry" |
| Q90506533 | B cell and B cell-related pathways for novel cancer treatments |
| Q89521129 | BRAF mutant metastatic colorectal cancers: new arrows in our quiver |
| Q49922743 | Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review |
| Q91754859 | Biomarker-guided therapy for colorectal cancer: strength in complexity |
| Q64881806 | Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events. |
| Q94464383 | CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers |
| Q94526290 | Cautious optimism-the current role of immunotherapy in gastrointestinal cancers |
| Q92197686 | Challenge of immune-mediated adverse reactions in the emergency department |
| Q92451360 | Characteristics of BRAF V600E Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients |
| Q61797416 | Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts |
| Q58775775 | CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer |
| Q64081166 | CheckMate-032 Study: promising efficacy with nivolumab-based immunotherapy in pretreated esophagogastric cancer |
| Q60929939 | Checkpoint inhibitors: What gastroenterologists need to know |
| Q92636004 | Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer |
| Q98215647 | Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea |
| Q89868154 | Colon Cancer: A Clinician's Perspective in 2019 |
| Q64229063 | Colorectal Cancer Biomarkers in the Era of Personalized Medicine |
| Q89625425 | Colorectal Cancer in the Adolescent and Young Adult Population |
| Q90834049 | Colorectal cancer |
| Q55411157 | Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells. |
| Q64910760 | Combination of CTLA-4 and PD-1 blockers for treatment of cancer. |
| Q64094675 | Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies |
| Q90074156 | Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents |
| Q91045434 | Comprehensive analysis of POLE and POLD1 Gene Variations identifies cancer patients potentially benefit from immunotherapy in Chinese population |
| Q90699218 | Comprehensive review of targeted therapy for colorectal cancer |
| Q91876747 | Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: A population-based cohort of metastatic colorectal cancer patients |
| Q57806327 | Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer |
| Q92256962 | Current Update of Laboratory Molecular Diagnostics Advancement in Management of Colorectal Cancer (CRC) |
| Q91830988 | Current and emerging biomarkers in metastatic colorectal cancer |
| Q90437250 | Current challenges in the implementation of precision oncology for the management of metastatic colorectal cancer |
| Q88621871 | Current clinical topics of Lynch syndrome |
| Q55715408 | Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy. |
| Q59350349 | Current status of immunotherapy in metastatic colorectal cancer |
| Q58561585 | Cytokines in clinical cancer immunotherapy |
| Q60958246 | Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer |
| Q92723462 | Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer |
| Q99418510 | Cytotoxic CD8+ T cells in cancer and cancer immunotherapy |
| Q90714354 | DNA Mismatch Repair Deficiency and Immune Checkpoint Inhibitors in Gastrointestinal Cancers |
| Q57057014 | DNA repair defects and implications for immunotherapy |
| Q99406919 | Delivery of Personalized Care for Locally Advanced Rectal Cancer: Incorporating Pathological, Molecular Genetic, and Immunological Biomarkers Into the Multimodal Paradigm |
| Q90537861 | Detection of Three Distinct Clonal Populations Using Circulating Cell Free DNA: A Cautionary Note on the Use of Liquid Biopsy |
| Q89944648 | Determinants of Resistance to Checkpoint Inhibitors |
| Q104617073 | Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule |
| Q92831974 | Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer |
| Q94604205 | Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study |
| Q90248599 | Effect of Tumor Location on Clinicopathological and Molecular Markers in Colorectal Cancer in Eastern China Patients: An Analysis of 2,356 Cases |
| Q96018897 | Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer |
| Q104105690 | Enhancing anti-tumour efficacy with immunotherapy combinations |
| Q96951688 | Establishment of a novel gene panel as a biomarker of immune checkpoint inhibitor response |
| Q92185841 | Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer |
| Q89849938 | Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions |
| Q64072331 | Exploiting DNA repair defects in colorectal cancer |
| Q92231021 | Exploring the best treatment options for BRAF-mutant metastatic colon cancer |
| Q94546984 | FOLFOX Chemotherapy Ameliorates CD8 T Lymphocyte Exhaustion and Enhances Checkpoint Blockade Efficacy in Colorectal Cancer |
| Q98466723 | Friend or Foe: Prognostic and Immunotherapy Roles of BTLA in Colorectal Cancer |
| Q90416214 | Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives |
| Q90748460 | Genetic predisposition to colorectal cancer: syndromes, genes, classification of genetic variants and implications for precision medicine |
| Q92875475 | Gut Microbiome: A Promising Biomarker for Immunotherapy in Colorectal Cancer |
| Q90289012 | Gut microbiota in colorectal cancer: mechanisms of action and clinical applications |
| Q60939319 | How the V600E Mutation Defines a Distinct Subgroup of Colorectal Cancer: Molecular and Clinical Implications |
| Q64118532 | How to select colorectal cancer patients for personalized therapy |
| Q89668317 | IMblaze 370: lessons learned and future strategies in colorectal cancer treatment |
| Q58737377 | Immune blockade inhibitors and the radiation abscopal effect in gastrointestinal cancers |
| Q90679214 | Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms |
| Q90257606 | Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy |
| Q104286922 | Immunity, Immunotherapy, and Rectal Cancer: A Clinical and Translational Science Review |
| Q64081314 | Immuno-checkpoint inhibitors in metastatic esophago-gastric cancer |
| Q61799417 | Immunotherapeutic advances in gastrointestinal malignancies |
| Q92316369 | Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer |
| Q90131938 | Immunotherapy After Immunotherapy: Response Rescue in a Patient With Microsatellite Instability-high Colorectal Cancer Post-Pembrolizumab |
| Q91654858 | Immunotherapy and radiation therapy for gastrointestinal malignancies: hope or hype? |
| Q92461421 | Immunotherapy in colorectal cancer: rationale, challenges and potential |
| Q89910785 | Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours? |
| Q90113851 | Immunotherapy, Inflammation and Colorectal Cancer |
| Q90697982 | Implications of driver genes associated with a high tumor mutation burden identified using next-generation sequencing on immunotherapy in hepatocellular carcinoma |
| Q64994221 | Importance of genetic screens in precision oncology. |
| Q89495092 | Innate Lymphoid Cells in Colorectal Cancers: A Double-Edged Sword |
| Q57288172 | Inter-tumoral heterogeneity of CD3 and CD8 T-cell densities in the microenvironment of DNA mismatch repair-deficient colon cancers: implications for prognosis |
| Q90007129 | Interferon-Induced IDO1 Mediates Radiation Resistance and Is a Therapeutic Target in Colorectal Cancer |
| Q92882758 | Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repair-Deficient Colorectal Cancer |
| Q91729048 | Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition |
| Q90279899 | KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer - practical implications for the clinician |
| Q92580562 | KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer |
| Q97595643 | Landscape of somatic single nucleotide variants and indels in colorectal cancer and impact on survival |
| Q91788117 | Learning from clinical trials of neoadjuvant checkpoint blockade |
| Q92425347 | Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade |
| Q64933332 | Maximising clinical benefit with adequate patient management beyond the second line in mCRC. |
| Q93000881 | Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major Human Cancers to Next Generation Anti-CTLA-4 Antibodies |
| Q92875307 | Mechanisms of immunogenicity in colorectal cancer |
| Q91361655 | Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours |
| Q91831000 | Metastatic colorectal cancer: therapeutic options for treating refractory disease |
| Q90749821 | Microsatellite Instability: Diagnosis, Heterogeneity, Discordance, and Clinical Impact in Colorectal Cancer |
| Q90448647 | Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives |
| Q92757665 | Microsatellite instability: a review of what the oncologist should know |
| Q89521012 | Mismatch repair deficiency/microsatellite instability testing as predictive immunotherapy biomarkers-possible diagnostic missteps trusting a single method |
| Q64990522 | Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. |
| Q59794745 | Molecular characterization and biomarker identification in colorectal cancer: Toward realization of the precision medicine dream |
| Q63441293 | Molecular subtypes in early colorectal cancer associated with clinical features and patient prognosis |
| Q64935738 | Molecular targeted therapy of BRAF-mutant colorectal cancer. |
| Q92059453 | Mouse models of colorectal cancer: Past, present and future perspectives |
| Q64101405 | Mucinous colorectal adenocarcinoma: clinical pathology and treatment options |
| Q90190001 | Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy |
| Q91595919 | Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers |
| Q90428632 | New insights in predictive determinants of the tumor immune microenvironment for immune checkpoint inhibition: a never ending story? |
| Q90695296 | New therapies and insights into the changing landscape of colorectal cancer |
| Q87857715 | Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer |
| Q55403266 | Non-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors. |
| Q91831006 | Optimizing biologic sequencing in metastatic colorectal cancer: first line and beyond |
| Q62897954 | Outcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registry |
| Q96303222 | PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake |
| Q64085542 | PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer |
| Q92431353 | Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy |
| Q99635705 | Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018) |
| Q98289686 | Photothermal therapy technology of metastatic colorectal cancer |
| Q93163585 | Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG) |
| Q99630568 | Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors |
| Q64997225 | Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer. |
| Q90357478 | Prolonged Treatment Response to Pembrolizumab in a Patient with Pretreated Metastatic Colon Cancer and Lynch Syndrome |
| Q88646346 | Promising New Agents for Colorectal Cancer |
| Q99635703 | Prophylactic chemotherapeutic hyperthermic intraperitoneal perfusion reduces peritoneal metastasis in gastric cancer: a retrospective clinical study |
| Q57821644 | Recent advances in understanding colorectal cancer |
| Q92061487 | Recent trends in the age at diagnosis of colorectal cancer in the US National Cancer Data Base, 2004-2015 |
| Q93375221 | Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial |
| Q97075816 | Regorafenib Versus Nivolumab After Sorafenib Failure: Real-World Data in Patients With Hepatocellular Carcinoma |
| Q90639891 | Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer |
| Q58783248 | Report from the 19th annual Western Canadian Gastrointestinal Cancer Consensus Conference; Winnipeg, Manitoba; 29-30 September 2017 |
| Q92381922 | Report from the 20th annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; 28-29 September 2018 |
| Q89668321 | Resistance of the stable-towards more precise prediction of response to immune checkpoint blockade in microsatellite-unstable cancer patients |
| Q64269548 | Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer |
| Q90559801 | Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial |
| Q57174372 | Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer |
| Q90627128 | SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018) |
| Q92418561 | Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer |
| Q64114423 | Selecting treatment options in refractory metastatic colorectal cancer |
| Q99240956 | Severe cytomegalovirus gastritis after pembrolizumab in a patient with melanoma |
| Q99552006 | Standard therapies: solutions for improving therapeutic effects of immune checkpoint inhibitors on colorectal cancer |
| Q59127261 | Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report |
| Q100526092 | Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era |
| Q92708769 | TIM-3 in endometrial carcinomas: an immunotherapeutic target expressed by mismatch repair-deficient and intact cancers |
| Q92306520 | Targeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in Review |
| Q92747984 | Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer |
| Q90050585 | The Crohn's-Like Lymphoid Reaction to Colorectal Cancer-Tertiary Lymphoid Structures With Immunologic and Potentially Therapeutic Relevance in Colorectal Cancer |
| Q92193162 | The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer |
| Q95661063 | The FBW7-MCL-1 axis is key in M1 and M2 macrophage-related colon cancer cell progression: validating the immunotherapeutic value of targeting PI3Kγ |
| Q90241038 | The Interplay of Autophagy and Tumor Microenvironment in Colorectal Cancer-Ways of Enhancing Immunotherapy Action |
| Q99605605 | The Macrophages-Microbiota Interplay in Colorectal Cancer (CRC)-Related Inflammation: Prognostic and Therapeutic Significance |
| Q61449923 | The Prognostic and Therapeutic Value of PD-L1 in Glioma |
| Q94564126 | The Role of Palliative Surgery for Malignant Bowel Obstruction and Perforation in Advanced Microsatellite Instability-High Colorectal Carcinoma in the Era of Immunotherapy: Case Report |
| Q64256609 | The Tolerogenic Function of Regulatory T Cells in Pregnancy and Cancer |
| Q92642235 | The Tumor Microenvironment in Colorectal Cancer Therapy |
| Q58799989 | The Winding Roadmap of Biomarkers toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer |
| Q92214210 | The current state of molecular testing in the treatment of patients with solid tumors, 2019 |
| Q64268768 | The density of Tbet+ tumor-infiltrating T lymphocytes reflects an effective and druggable preexisting adaptive antitumor immune response in colorectal cancer, irrespective of the microsatellite status |
| Q89520785 | The evolving treatment paradigm for BRAF V600 mutant colorectal cancer |
| Q98290541 | The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China |
| Q92463703 | The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy |
| Q93182663 | The requirement for immune infiltration and organization in the tumor microenvironment for successful immunotherapy in prostate cancer |
| Q64981981 | The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis. |
| Q99580578 | The targeted delivery of interleukin-12 to the carcinoembryonic antigen increases the intratumoral density of NK and CD8+ T cell in an immunocompetent mouse model of colorectal cancer |
| Q89668314 | Treating BRAFV600E metastatic colorectal patients in 2019: a BEACON of hope? |
| Q91649938 | Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis |
| Q58804439 | Tumor mutational burden (TMB) as a biomarker of response to immunotherapy in small cell lung cancer |
| Q90473178 | Tumor-Infiltrating Immunosuppressive Cells in Cancer-Cell Plasticity, Tumor Progression and Therapy Response |
| Q96576389 | Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies |
| Q92130522 | Uncovering Potential Therapeutic Targets in Colorectal Cancer by Deciphering Mutational Status and Expression of Druggable Oncogenes |
| Q64262617 | Update on systemic therapy for colorectal cancer: biologics take sides |
| Q92236392 | Updates in version 2019 of CSCO guidelines for colorectal cancer from version 2018 |
| Q93012758 | WRN helicase is a synthetic lethal target in microsatellite unstable cancers |
| Q64054862 | Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cells |
| Q89862626 | [Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version)] |
| Q99632545 | [Development of programmed death receptor-1 and programmed death receptor-1 ligand in oral squamous cell carcinoma] |
| Q92592939 | cGAS/STING axis mediates a topoisomerase II inhibitor-induced tumor immunogenicity |
| Q91828889 | miR-140-3p Suppresses Cell Growth And Induces Apoptosis In Colorectal Cancer By Targeting PD-L1 |
| Q59125292 | miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis |
Search more.